For the year ending 2025-12-31, TSHA had $180,895K increase in cash & cash equivalents over the period. -$93,828K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -108,995 |
| Depreciation expense | 1,145 |
| Stock-based compensation | 13,298 |
| Research and development license expense | 3,000 |
| Change in fair value of warrant liability | 1,199 |
| Non-cash change in fair value of term loan | 832 |
| Debt issuance costs expensed under the fair value option | 147 |
| Non-cash lease expense | 1,359 |
| Other | -296 |
| Prepaid expenses and other assets | 1,734 |
| Accounts payable | -153 |
| Accrued expenses and other liabilities | 6,289 |
| Deferred revenue | -9,773 |
| Net cash used in operating activities | -93,090 |
| Purchase of property, plant and equipment | 738 |
| Other | -134 |
| Net cash used in investing activities | -604 |
| Proceeds from issuance of common stock and pre-funded warrants from underwritten public offering, net of underwriting discounts and sales commissions and other offering costs | 215,646 |
| Proceeds from issuance of common stock pursuant to at-the-market offering, net of sales commissions and other offering costs | 48,435 |
| Prepayment of 2023 trinity term loan | 40,612 |
| Proceeds from 2025 trinity term loan, net | 49,853 |
| Proceeds from issuance of common stock upon exercise of warrants | 225 |
| Proceeds from common stock issuances under espp | 159 |
| Proceeds from stock option exercises | 1,220 |
| Other | -337 |
| Net cash provided by financing activities | 274,589 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 180,895 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 141,636 |
| Cash, cash equivalents and restricted cash at the end of the period | 322,531 |
Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. (TSHA)